Teva partners with Israeli institutes for early-stage drug research

World

Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.

FILE PHOTO: The logo of Teva Pharmaceutical Industries is seen during a news conference by its CEO, Kare Schultz, to discuss the company's 2019 outlooks in Tel Aviv, Israel February 19, 2019. REUTERS/Amir Cohen/File Photo

Share this content

Bookmark

JERUSALEM: Teva Pharmaceutical Industries on Monday signed research agreements with two leading Israeli academic institutes, a move to boost its early-stage drug development with a focus on cancer treatments.

The world's largest generic drugmaker has been looking to expand its specialty portfolio and said it is seeking more than 400 new laboratories within Israeli academia.

Advertisement

Advertisement

A partnership with Tel Aviv University will focus on research and development in cancer and brain studies, while a collaboration with Read More – Source